Omeros Corp: Below. Substantially Concurrent With The Closing Of Such Transaction, The Company Utilized A Portion Of The $240.0 Million Upfront Payment That It Received To Repay All Outstanding Obligations Under The Credit And Guarantee Agreement, Dated June 3, 2024 (the “credit Agreement”), Among The Company, The Various Lenders Party Thereto, And Wilmington Savings Fund Society, Fsb, As Administrative Agent And Collateral Agent. The Retirement Included Prepayment Of The $67.1 Million Outstanding Term Loan Under The Credit Agreement, A $3.4million Mandatory Prepayment Premium, $2.0 Million Of Incurredinterest, And Approximately $0.1million Of Transaction Related Expenses. Repayment Of The Company’s Obligations Under The Credit Agreement Resulted In The Simultaneous Release In Full Of All Liens And Covenants Thereunder, Including The Covenant Requiring The Company To Maintain At All Times A Minimum Of $25.0 Million Of Unrestricted Cash, Cash Equivalents And Shortterm Investments, Releasing Such $25.0 Million Into The Company's Working Capital Available For Use. Upon The Occurrence Of Such Events, The Credit Agreement Was Terminated

Show full article

This functionality is available for registred users only

• Full name
  Omeros Corporation
• Registration country
  USA
• Industry
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***